Archipelago Biotechnology Indonesia (Aka. ARCHI BIOTECH) is a microbial biotechnology start-up company based in The Sumbawa Island, West Nusa Tenggara Province, Indonesia. We aim to democratizing the use of personalized microbial solution (e.g., microbiome engineering) to tackle various problems related to the health, food, agriculture, renewable energy and environment.
Embarking on Scientific Endeavor: Collecting Samples atop Mount Tambora to Explore Actinomycetes Bacteria for Novel Antibiotic Compounds.
The COVID 360 project introduced rapid surface testing, a first in Indonesia, to combat COVID-19 spread. Focused on user-friendly testing kits, stakeholder engagement, and testing across Sumbawa District, our goal was swift and accurate detection of COVID-19 on surfaces.
On Friday, February 23, 2024, Archi Biotech and the Faculty of Life Sciences and Technology at Sumbawa University of Technology formalized a significant partnership through the signing of a Memorandum
READ MORE
Archi Biotech and RSUP H.L. Manambai Abdulkadir NTB Join Forces for Healthcare Innovation On Friday, February 23, 2024, Archi Biotech and RSUP H.L. Manambai Abdulkadir NTB took a significant step
READ MORE
Sumbawa, Indonesia – Archi Biotech, a leading player in the biotechnology sector, has achieved yet another milestone by securing a coveted spot in the Let Be Indonesia incubation program. The
READ MORE
Sumbawa Besar, Indonesia – Archipelago Biotechnology Indonesia proudly unveils its latest endeavor, the social project titled “Covid 360: Clean Surface, Healthy People,” aimed at pioneering a groundbreaking system for the
READ MORE
